Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.
New product launches in the premium segments as well as increased focus on direct channel distributions and improving cost synergies should help maintain growth. We reiterate our BUY rating on the stock with a revised target price of Rs. 413 based on 43x FY22E adj. EPS. Pandemic hits volumes impacting topline Q1FY21 revenue declined 11.1% YoY to Rs. 1,925cr due to severe impact in domestic business in April, even as volume recovery can be seen from May onwards (upwards of 3.0% YoY). Revenue from India operations stood at Rs. 1,480cr (-14.5% YoY)....
RBL Bank Ltd. is a fast-growing private sector bank with a network of 386 branches and over 8.5 million customers. It offers various services, including corporate and institutional banking, commercial banking, retail...
GMM Pfaudler Ltd (GMM), for Q1FY21, reported a weak set of numbers. Revenue marginally grew by 2.8% YoY to INR 1544mn (est INR 1721mn) mainly due to fewer production days (two months) led by the extended lockdown. However, Q1FY21 revenue includes execution of a deferred order of Q4FY20 worth INR 150mn-200mn.EBITDA remained flat at INR275mn (est INR342mn) with 55ps YoY decline in margin from 18.4% in Q1FY20 to 17.8% in Q1FY21, due to adverse product mix mainly impacted by proprietary business, where EBIT margin declined by 755bps on YoY basis with 23% contribution in consolidated revenue. However, the Heavy engineering business has reported a strong growth of 565% in revenue along with 21.3% EBIT margin (vs 2.8%YoY) in Q1FY21. This, we believe partly led...
Background: Orient Cement, a CK Birla group company, formed in 2012 following the demerger from Orient Paper and Industries ltd, is a mid-sized south based cement manufacturer. The company is one of the leading cement manufacturers in India with a capacity of 8 MTPA with clinker manufacturing capacity 5.5 MTPA and captive power capacity of 95MW. The Company operates 3 manufacturing facilities, located at Devapur (3 MTPA) in Telangana, Chittapur (3 MTPA) in Karnataka and...
Outlook & Valuation: We downgrade our revenue estimates for FY21E / FY22E by 4.6% / 4.6% to Rs. 32.9 Bn / Rs. 36.3 Bn for FY21E / FY22E. We downgrade our EBITDA margins for FY21E / FY22E by 50 bps to 20.6%/21.9% due to fixed nature of personal cost.
31 July 2020 Essel Propack Essel Propack (ESEL) reported strong growth (13.6% constant currency growth) across geographies amid the COVID-19 crisis, primarily led by East Asia Pacific (EAP) and Europe. The ramp-up in operations led to an increase in operating leverage in EAP and Europe. Factoring a beat to our estimates for the quarter, we increase our earnings estimate for FY21/FY22E by 20%/12%, after considering a further ramp-up in operations and new launches across geographies, to arrive at TP of INR253. strong performance in EAP and Europe. EBITDA margins expanded by 250bp is attributable to a better product mix and operating leverage, including INR380m). AMESA revenue declined 3% YoY to INR2.2b. EBIT margins contracted by 190bp to 7.3% and EBIT decreased to INR160m (down 23% YoY). EAP revenue increased by 46% YoY to INR2b on a growing business pipeline in China and increased focus on regional players. The EBIT margin expanded 880bp to 21.7%, with EBIT at INR438m (up 2.
EBITDA margin expanded at higher rate of 590bp YoY with superior product mix and controlled opex. We remain positive on AJP on its new launches, rising share in key markets of the US/India/Asia/Africa and improved operating leverage. Re-iterate In the branded formulation segment, AJP witnessed 15% YoY decline in India, while it delivered 27.8%/17.4% YoY growth in Asia/Africa in 1QFY21. AJP has strong pipeline of registration in both Asia/Africa branded segment. We expect Africa branded segment to deliver better 12% CAGR over FY20-22E to INR4.3b owing to increased offerings and better reach. AJPs US sales grew 46% YoY due to increased traction in existing With 19 ANDAs pending approval, the company has an intention to file 10-12 ANDAs annually. Considering 6-7 launches in FY21, we expect AJP to garner 20% CAGR in US sales over FY20-22E to INR7.3b in this segment.
31 July 2020 Despite COVID-19-led industry-wide slowdown in Domestic Formulations (DF), Torrent Pharma (TRP) outperformed owing to its strong presence in the Chronic segment. The Germany business is expected to see revival 2HFY21 onwards. Growth in the US hinges on the Dahej/Indrad regulatory resolution. from COVID-19-led weakness in the India/Brazil business, b) the Germany business returning to normal, and c) reduced opex aiding better profitability. We value TRP at 24x 12M forward earnings and roll our TP to INR2,565. Maintain Neutral on limited upside from current levels. ROW sales grew 31% YoY to INR2.3b (11% of sales), driving overall growth in revenue. India sales grew 2% YoY (INR9.3b; 45% of sales). Brazil revenue (7% of sales) was down 20% YoY to INR1.4b. In constant currency, Brazil sales were steady on a YoY basis.
The EBITDA margin contracted considerably to 11% in the quarter (from 21% in FY20) due to lower revenue from Complex Hospital Generics and The deferment of surgeries in the Hospital segment impacted overall performance in PIELs Pharma segment. However, the phase-wise easing of the lockdown is improving the outlook across the CDMO and Complex The company will roll out retail lending products such as LAP and small business loans around the Diwali festival in 1520 towns. The Pharma business is witnessing increased traction, and the recent stake sale has set a benchmark for its valuation. INR34b of the INR37b Pharma stake sale to Carlyle would go back to PIEL. While PIELs Pharma business was impacted by COVID-19, management indicated U-shaped recovery over the next two to three quarters. We keep credit costs elevated over the next two years The Pharma business is witnessing increased traction.
